Case report: golimumab-related osteonecrosis of the jaw

Yohaann A Ghosh; Jonathon Pullara; Rishabh Rattan; James C Melville

doi:10.1016/j.oooo.2023.05.017

Case report: golimumab-related osteonecrosis of the jaw

Oral Surg Oral Med Oral Pathol Oral Radiol. 2023 Nov;136(5):e149-e152. doi: 10.1016/j.oooo.2023.05.017. Epub 2023 May 28.

Authors

Yohaann A Ghosh¹, Jonathon Pullara², Rishabh Rattan², James C Melville³

Affiliations

¹ School of Medicine and Dentistry, Griffith University, Gold Coast, Australia; Integrated Prosthetics and Reconstruction, Department of Head and Neck Surgery, Sydney, Australia.
² Bernard and Gloria Pepper Katz Department of Oral and Maxillofacial Surgery, the University of Texas Health Science Center at Houston, Houston, TX, USA.
³ Bernard and Gloria Pepper Katz Department of Oral and Maxillofacial Surgery, the University of Texas Health Science Center at Houston, Houston, TX, USA. Electronic address: James.c.melville@uth.tmc.edu.

PMID: 37661466
DOI: 10.1016/j.oooo.2023.05.017

Abstract

Medication-related osteonecrosis of the jaw is an uncommon but highly morbid adverse event of certain medical therapies. Although classically induced by bisphosphonates, the recent advent of monoclonal antibodies is contributing to a rise in cases. In this case report, we present a rare case of golimumab-associated medication-related osteonecrosis of the jaw and discuss the possible mechanisms of pathogenesis.

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal / adverse effects
Bisphosphonate-Associated Osteonecrosis of the Jaw* / etiology
Bone Density Conservation Agents* / adverse effects
Diphosphonates / adverse effects
Humans
Jaw / pathology
Jaw Diseases* / chemically induced
Osteonecrosis* / chemically induced
Osteonecrosis* / diagnostic imaging

Substances

golimumab
Diphosphonates
Antibodies, Monoclonal
Bone Density Conservation Agents